Global healthcare leader Abbott has announced the launch of the HBsAg Next Qualitative solution in India to enhance detection of the hepatitis B virus (HBV). This assay will help improve patient outcomes while maintaining safe blood supplies. This highly sensitive chemiluminescent microparticle immunoassay (CMIA) assists in the early and enhanced detection of HBV in human serum and plasma (blood) samples and in population screening. A chemiluminescent immunoassay is a variation of the standard enzyme immunoassay, a biochemical technique used in immunology. Early identification of HBV infections allows patients to receive the necessary care to prevent or delay progression of advanced liver diseases. Moreover, it also reduces the risk of transmission. The HBsAg Next Qualitative assay is an advanced, next generation solution to better support the earlier detection of HBV. It detects HBV surface antigen (HBsAg) in human serum and plasma. Moreover, it overcomes traditional challenges by showcasing the highest level of assay performance required to detect infection in immunocompromised groups. Dr. Jaganathan Sickan, senior associate director, medical affairs, Core Diagnostics at Abbott said,
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!